{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:06:42Z","timestamp":1787771202083,"version":"build-2784847793"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004166","name":"Warszawski Uniwersytet Medyczny","doi-asserted-by":"publisher","award":["1M24\/1\/M\/MBM\/N\/21\/21"],"award-info":[{"award-number":["1M24\/1\/M\/MBM\/N\/21\/21"]}],"id":[{"id":"10.13039\/501100004166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["2015\/19\/D\/NZ6\/01303"],"award-info":[{"award-number":["2015\/19\/D\/NZ6\/01303"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Hepatitis C virus (HCV) is a primary hepatotropic pathogen responsible for acute and chronic hepatitis C, however, it can also cause \u201coccult\u201d infection (OCI), defined as the presence of the virus\u2019 genetic material in hepatocytes and\/or peripheral blood cells, but not in plasma\/serum. Assessment of the sustained virologic response (SVR) after treatment with direct-acting antivirals (DAA) is based exclusively on HCV-RNA testing in plasma\/serum, which may preclude the diagnosis of post-treatment OCI. Possible clinical consequences of OCI were described previously, but its occurrence after DAA-based antiviral treatment programs and determinants of the virus persistence are not fully elucidated. The aim of this study was to assess the incidence of post-treatment OCI after successful DAA-based treatment and to identify clinical and immunological factors associated with this phenomenon. In 97 patients treated with DAA, HCV-RNA was tested by RT-PCR in peripheral blood mononuclear cells (PBMC) at baseline (i.e., before the onset of treatment) and at the time of SVR assessment. Before treatment, HCV-RNA was detectable in all patients\u2019 PBMC. All subjects responded to therapy according to the clinical criteria, but 9 (9.3%) patients revealed the HCV-RNA in PBMC at SVR. In most of these cases, post-DAA OCI was related to switch of the dominant infecting genotype. Post-treatment OCI was characterized by significantly lower pre-treatment HCV viral load and lower expression of Tim-3 (T-cell immunoglobulin and mucin domain-containing protein 3) on CD8<jats:sup>+<\/jats:sup> T-cells. Our results imply that post-treatment OCI may be related to lower pretreatment viral load as well as distinct pre-existing immune exhaustion status.<\/jats:p>","DOI":"10.1038\/s41598-025-05084-z","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T08:05:56Z","timestamp":1749197156000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Persistence of hepatitis C virus in peripheral blood mononuclear cells of patients who achieved sustained virological response following treatment with direct-acting antivirals is associated with a distinct pre-existing immune exhaustion status"],"prefix":"10.1038","volume":"15","author":[{"given":"Sylwia","family":"Osuch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Kazek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina","family":"Emmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Berak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Radkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7924-7852","authenticated-orcid":false,"given":"Kamila","family":"Cort\u00e9s-Fendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,6]]},"reference":[{"issue":"9973","key":"5084_CR1","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/S0140-6736(14)62401-6","volume":"385","author":"DP Webster","year":"2015","unstructured":"Webster, D. P., Klenerman, P. & Dusheiko, G. M. Hepatitis C. Lancet 385(9973), 1124\u20131135 (2015).","journal-title":"Lancet"},{"issue":"3","key":"5084_CR2","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s12072-015-9684-3","volume":"10","author":"K Gill","year":"2016","unstructured":"Gill, K. et al. Hepatitis C virus as a systemic disease: reaching beyond the liver. Hepatol Int 10(3), 415\u2013423 (2016).","journal-title":"Hepatol Int"},{"key":"5084_CR3","doi-asserted-by":"publisher","first-page":"349","DOI":"10.5604\/17322693.1199988","volume":"70","author":"A Pawelczyk","year":"2016","unstructured":"Pawelczyk, A. Consequences of extrahepatic manifestations of hepatitis C viral infection (HCV). Postepy Hig. Med. Dosw. (Online) 70, 349\u2013359 (2016).","journal-title":"Postepy Hig. Med. Dosw. (Online)"},{"issue":"1","key":"5084_CR4","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/hep.20518","volume":"41","author":"M Radkowski","year":"2005","unstructured":"Radkowski, M. et al. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepatology 41(1), 106\u2013114 (2005).","journal-title":"Hepatology"},{"key":"5084_CR5","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1186\/1743-422X-10-346","volume":"10","author":"A Pawelczyk","year":"2013","unstructured":"Pawelczyk, A. et al. Detection of hepatitis C virus (HCV) negative strand RNA and NS3 protein in peripheral blood mononuclear cells (PBMC): CD3+, CD14+ and CD19+. Virol J 10, 346 (2013).","journal-title":"Virol J"},{"issue":"12","key":"5084_CR6","doi-asserted-by":"publisher","first-page":"3986","DOI":"10.1182\/blood.V95.12.3986.012k39_3986_3989","volume":"95","author":"M Radkowski","year":"2000","unstructured":"Radkowski, M. et al. Detection of active hepatitis C virus and hepatitis G virus\/GB virus C replication in bone marrow in human subjects. Blood 95(12), 3986\u20133989 (2000).","journal-title":"Blood"},{"issue":"2","key":"5084_CR7","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1128\/JVI.76.2.600-608.2002","volume":"76","author":"M Radkowski","year":"2002","unstructured":"Radkowski, M. et al. Search for hepatitis C virus negative-strand RNA sequences and analysis of viral sequences in the central nervous system: evidence of replication. J Virol 76(2), 600\u2013608 (2002).","journal-title":"J Virol"},{"issue":"24","key":"5084_CR8","doi-asserted-by":"publisher","first-page":"5874","DOI":"10.3390\/jcm10245874","volume":"10","author":"A Wroblewska","year":"2021","unstructured":"Wroblewska, A., Bielawski, K. P. & Sikorska, K. Occult infection with hepatitis C virus: Looking for clear-cut boundaries and methodological consensus. J. Clin. Med. 10(24), 5874 (2021).","journal-title":"J. Clin. Med."},{"issue":"3","key":"5084_CR9","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0973-6883(11)60130-8","volume":"1","author":"TN Pham","year":"2011","unstructured":"Pham, T. N. & Michalak, T. I. Occult hepatitis C virus infection and its relevance in clinical practice. J. Clin. Exp. Hepatol. 1(3), 185\u2013189 (2011).","journal-title":"J. Clin. Exp. Hepatol."},{"issue":"5","key":"5084_CR10","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/hep.22802","volume":"49","author":"SA MacParland","year":"2009","unstructured":"MacParland, S. A. et al. Hepatitis C virus persisting after clinically apparent sustained virological response to antiviral therapy retains infectivity in vitro. Hepatology 49(5), 1431\u20131441 (2009).","journal-title":"Hepatology"},{"issue":"2","key":"5084_CR11","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/j.1365-2893.2011.01442.x","volume":"19","author":"TN Pham","year":"2012","unstructured":"Pham, T. N. et al. Hepatitis C virus persistence after sustained virological response to antiviral therapy in patients with or without past exposure to hepatitis B virus. J. Viral Hepat. 19(2), 103\u2013111 (2012).","journal-title":"J. Viral Hepat."},{"issue":"10","key":"5084_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0140312","volume":"10","author":"AY Chen","year":"2015","unstructured":"Chen, A. Y. et al. Persistence of hepatitis C virus traces after spontaneous resolution of hepatitis C. PLoS ONE 10(10), e0140312 (2015).","journal-title":"PLoS ONE"},{"issue":"2","key":"5084_CR13","doi-asserted-by":"publisher","first-page":"155","DOI":"10.14218\/JCTH.2017.00053","volume":"6","author":"A Austria","year":"2018","unstructured":"Austria, A. & Wu, G. Y. Occult hepatitis C virus infection: A review. J. Clin. Transl. Hepatol. 6(2), 155\u2013160 (2018).","journal-title":"J. Clin. Transl. Hepatol."},{"key":"5084_CR14","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/579147","volume":"2015","author":"BM Attar","year":"2015","unstructured":"Attar, B. M. & Van Thiel, D. A new twist to a chronic HCV infection: Occult hepatitis C. Gastroenterol. Res. Pract. 2015, 579147 (2015).","journal-title":"Gastroenterol. Res. Pract."},{"key":"5084_CR15","unstructured":"Cort\u00e9s-Mancera, F. M., J.C.R.M., Germ\u00e1n Osorio, Hoyos, S., Correa, G., Navas, M. C. Occult hepatitis C virus infection in a re-transplanted patient with liver failure of unknown etiology. Rev. Col. Gastroenterol. 25 (2010)."},{"key":"5084_CR16","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.ebiom.2019.07.043","volume":"46","author":"Y Wang","year":"2019","unstructured":"Wang, Y. et al. Detection of residual HCV-RNA in patients who have achieved sustained virological response is associated with persistent histological abnormality. EBioMedicine 46, 227\u2013235 (2019).","journal-title":"EBioMedicine"},{"issue":"1","key":"5084_CR17","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1086\/380202","volume":"189","author":"I Castillo","year":"2004","unstructured":"Castillo, I. et al. Occult hepatitis C virus infection in patients in whom the etiology of persistently abnormal results of liver-function tests is unknown. J. Infect. Dis. 189(1), 7\u201314 (2004).","journal-title":"J. Infect. Dis."},{"issue":"3","key":"5084_CR18","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1136\/gut.47.3.429","volume":"47","author":"C Berasain","year":"2000","unstructured":"Berasain, C. et al. Pathological and virological findings in patients with persistent hypertransaminasaemia of unknown aetiology. Gut 47(3), 429\u2013435 (2000).","journal-title":"Gut"},{"issue":"3","key":"5084_CR19","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1053\/j.gastro.2016.11.002","volume":"152","author":"S Elmasry","year":"2017","unstructured":"Elmasry, S. et al. Detection of occult hepatitis C virus infection in patients who achieved a sustained virologic response to direct-acting antiviral agents for recurrent infection after liver transplantation. Gastroenterology 152(3), 550-553 e8 (2017).","journal-title":"Gastroenterology"},{"issue":"7","key":"5084_CR20","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1002\/jmv.21483","volume":"81","author":"I Castillo","year":"2009","unstructured":"Castillo, I. et al. Hepatitis C virus infection in the family setting of patients with occult hepatitis C. J. Med. Virol. 81(7), 1198\u20131203 (2009).","journal-title":"J. Med. Virol."},{"key":"5084_CR21","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1146\/annurev-pharmtox-011112-140254","volume":"53","author":"JJ Kiser","year":"2013","unstructured":"Kiser, J. J. & Flexner, C. Direct-acting antiviral agents for hepatitis C virus infection. Annu. Rev. Pharmacol. Toxicol. 53, 427\u2013449 (2013).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"6","key":"5084_CR22","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1093\/cid\/cix457","volume":"65","author":"C Boschi","year":"2017","unstructured":"Boschi, C. et al. Hepatitis C virus relapse 78 weeks after completion of successful direct-acting therapy. Clin. Infect. Dis. 65(6), 1051\u20131053 (2017).","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"5084_CR23","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jhep.2013.02.009","volume":"59","author":"E Lawitz","year":"2013","unstructured":"Lawitz, E. et al. A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450\/r, ABT-072) and ribavirin in IL28B C\/C patients with chronic hepatitis C genotype 1. J. Hepatol. 59(1), 18\u201323 (2013).","journal-title":"J. Hepatol."},{"issue":"7","key":"5084_CR24","doi-asserted-by":"publisher","first-page":"723","DOI":"10.3851\/IMP2753","volume":"19","author":"P Barreiro","year":"2014","unstructured":"Barreiro, P. et al. Very late HCV relapse following triple therapy for hepatitis C. Antivir. Ther. 19(7), 723\u2013724 (2014).","journal-title":"Antivir. Ther."},{"issue":"9","key":"5084_CR25","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1002\/jmv.21866","volume":"82","author":"I Castillo","year":"2010","unstructured":"Castillo, I. et al. Diagnosis of occult hepatitis C without the need for a liver biopsy. J. Med. Virol. 82(9), 1554\u20131559 (2010).","journal-title":"J. Med. Virol."},{"issue":"4","key":"5084_CR26","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.3748\/wjg.v22.i4.1421","volume":"22","author":"R Gonzalez-Grande","year":"2016","unstructured":"Gonzalez-Grande, R. et al. New approaches in the treatment of hepatitis C. World J. Gastroenterol. 22(4), 1421\u20131432 (2016).","journal-title":"World J. Gastroenterol."},{"issue":"1","key":"5084_CR27","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/cid\/ciw676","volume":"64","author":"C Sarrazin","year":"2017","unstructured":"Sarrazin, C. et al. Late relapse versus hepatitis C virus reinfection in patients with sustained virologic response after sofosbuvir-based therapies. Clin. Infect. Dis. 64(1), 44\u201352 (2017).","journal-title":"Clin. Infect. Dis."},{"issue":"8","key":"5084_CR28","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1172\/JCI75938","volume":"124","author":"EG Meissner","year":"2014","unstructured":"Meissner, E. G. et al. Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. J. Clin. Investig. 124(8), 3352\u20133363 (2014).","journal-title":"J. Clin. Investig."},{"issue":"6","key":"5084_CR29","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1002\/hep.29921","volume":"68","author":"H Alao","year":"2018","unstructured":"Alao, H. et al. Baseline intrahepatic and peripheral innate immunity are associated with hepatitis C virus clearance during direct-acting antiviral therapy. Hepatology 68(6), 2078\u20132088 (2018).","journal-title":"Hepatology"},{"issue":"3","key":"5084_CR30","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s10238-019-00561-y","volume":"19","author":"A Wroblewska","year":"2019","unstructured":"Wroblewska, A. et al. Neutrocyte-to-lymphocyte ratio predicts the presence of a replicative hepatitis C virus strand after therapy with direct-acting antivirals. Clin. Exp. Med. 19(3), 401\u2013406 (2019).","journal-title":"Clin. Exp. Med."},{"key":"5084_CR31","doi-asserted-by":"publisher","first-page":"273","DOI":"10.2147\/IDR.S181638","volume":"12","author":"MA Mekky","year":"2019","unstructured":"Mekky, M. A. et al. Prevalence and predictors of occult hepatitis C virus infection among Egyptian patients who achieved sustained virologic response to sofosbuvir\/daclatasvir therapy: a multi-center study. Infect. Drug Resist. 12, 273\u2013279 (2019).","journal-title":"Infect. Drug Resist."},{"issue":"10","key":"5084_CR32","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1097\/MEG.0000000000001459","volume":"31","author":"AS Hanafy","year":"2019","unstructured":"Hanafy, A. S. et al. Residual hepatitis C virus in peripheral blood mononuclear cell as a risk factor for hepatocellular carcinoma after achieving a sustained virological response: A dogma or fiction. Eur. J. Gastroenterol. Hepatol. 31(10), 1275\u20131282 (2019).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"4","key":"5084_CR33","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jhep.2016.04.008","volume":"65","author":"M Reig","year":"2016","unstructured":"Reig, M. et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J. Hepatol. 65(4), 719\u2013726 (2016).","journal-title":"J. Hepatol."},{"issue":"3","key":"5084_CR34","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.jhep.2017.09.016","volume":"68","author":"N Fujiwara","year":"2018","unstructured":"Fujiwara, N. et al. Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. J. Hepatol. 68(3), 526\u2013549 (2018).","journal-title":"J. Hepatol."},{"key":"5084_CR35","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.3389\/fimmu.2019.01926","volume":"10","author":"A Vranjkovic","year":"2019","unstructured":"Vranjkovic, A. et al. Direct-acting antiviral treatment of HCV infection does not resolve the dysfunction of circulating CD8(+) T-cells in advanced liver disease. Front. Immunol. 10, 1926 (2019).","journal-title":"Front. Immunol."},{"issue":"4","key":"5084_CR36","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1053\/j.gastro.2017.06.012","volume":"153","author":"F Kanwal","year":"2017","unstructured":"Kanwal, F. et al. Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gastroenterology 153(4), 996-1005 e1 (2017).","journal-title":"Gastroenterology"},{"issue":"7","key":"5084_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0254243","volume":"16","author":"M Llorens-Revull","year":"2021","unstructured":"Llorens-Revull, M. et al. Partial restoration of immune response in hepatitis C patients after viral clearance by direct-acting antiviral therapy. PLoS ONE 16(7), e0254243 (2021).","journal-title":"PLoS ONE"},{"issue":"2","key":"5084_CR38","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1159\/000486812","volume":"7","author":"F Finkelmeier","year":"2018","unstructured":"Finkelmeier, F. et al. Risk of de novo hepatocellular carcinoma after HCV treatment with direct-acting antivirals. Liver Cancer 7(2), 190\u2013204 (2018).","journal-title":"Liver Cancer"},{"issue":"8","key":"5084_CR39","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","volume":"15","author":"EJ Wherry","year":"2015","unstructured":"Wherry, E. J. & Kurachi, M. Molecular and cellular insights into T cell exhaustion. Nat. Rev. Immunol. 15(8), 486\u2013499 (2015).","journal-title":"Nat. Rev. Immunol."},{"issue":"6","key":"5084_CR40","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/ni.2035","volume":"12","author":"EJ Wherry","year":"2011","unstructured":"Wherry, E. J. T cell exhaustion. Nat. Immunol. 12(6), 492\u2013499 (2011).","journal-title":"Nat. Immunol."},{"issue":"4","key":"5084_CR41","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1111\/j.1365-2567.2010.03255.x","volume":"129","author":"JS Yi","year":"2010","unstructured":"Yi, J. S., Cox, M. A. & Zajac, A. J. T-cell exhaustion: Characteristics, causes and conversion. Immunology 129(4), 474\u2013481 (2010).","journal-title":"Immunology"},{"key":"5084_CR42","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1146\/annurev-immunol-041015-055318","volume":"37","author":"LM McLane","year":"2019","unstructured":"McLane, L. M., Abdel-Hakeem, M. S. & Wherry, E. J. CD8 T cell exhaustion during chronic viral infection and cancer. Annu. Rev. Immunol. 37, 457\u2013495 (2019).","journal-title":"Annu. Rev. Immunol."},{"issue":"8","key":"5084_CR43","doi-asserted-by":"publisher","first-page":"799","DOI":"10.3390\/v12080799","volume":"12","author":"S Osuch","year":"2020","unstructured":"Osuch, S., Metzner, K. J. & Caraballo Cortes, K. Reversal of T Cell exhaustion in chronic HCV infection. Viruses 12(8), 799 (2020).","journal-title":"Viruses"},{"issue":"8","key":"5084_CR44","doi-asserted-by":"publisher","first-page":"4215","DOI":"10.1128\/JVI.02844-06","volume":"81","author":"C Boni","year":"2007","unstructured":"Boni, C. et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J. Virol. 81(8), 4215\u20134225 (2007).","journal-title":"J. Virol."},{"issue":"7562","key":"5084_CR45","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/nature14468","volume":"523","author":"EF McKinney","year":"2015","unstructured":"McKinney, E. F. et al. T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection. Nature 523(7562), 612\u2013616 (2015).","journal-title":"Nature"},{"issue":"10","key":"5084_CR46","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1038\/nm1482","volume":"12","author":"L Trautmann","year":"2006","unstructured":"Trautmann, L. et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat. Med. 12(10), 1198\u20131202 (2006).","journal-title":"Nat. Med."},{"issue":"22","key":"5084_CR47","doi-asserted-by":"publisher","first-page":"11398","DOI":"10.1128\/JVI.01177-06","volume":"80","author":"S Urbani","year":"2006","unstructured":"Urbani, S. et al. PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion. J Virol 80(22), 11398\u201311403 (2006).","journal-title":"J Virol"},{"key":"5084_CR48","doi-asserted-by":"publisher","first-page":"760","DOI":"10.3389\/fimmu.2017.00760","volume":"8","author":"J Bi","year":"2017","unstructured":"Bi, J. & Tian, Z. NK cell exhaustion. Front. Immunol. 8, 760 (2017).","journal-title":"Front. Immunol."},{"issue":"5","key":"5084_CR49","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1097\/COH.0000000000000092","volume":"9","author":"S Moir","year":"2014","unstructured":"Moir, S. & Fauci, A. S. B-cell exhaustion in HIV infection: The role of immune activation. Curr. Opin. HIV AIDS 9(5), 472\u2013477 (2014).","journal-title":"Curr. Opin. HIV AIDS"},{"issue":"16","key":"5084_CR50","doi-asserted-by":"publisher","first-page":"5644","DOI":"10.3390\/ijms21165644","volume":"21","author":"J Kemming","year":"2020","unstructured":"Kemming, J., Thimme, R. & Neumann-Haefelin, C. Adaptive immune response against hepatitis C virus. Int. J. Mol. Sci. 21(16), 5644 (2020).","journal-title":"Int. J. Mol. Sci."},{"issue":"33","key":"5084_CR51","doi-asserted-by":"publisher","first-page":"14733","DOI":"10.1073\/pnas.1009731107","volume":"107","author":"HT Jin","year":"2010","unstructured":"Jin, H. T. et al. Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proc. Natl. Acad. Sci. U. S. A. 107(33), 14733\u201314738 (2010).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"4","key":"5084_CR52","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.tim.2007.02.006","volume":"15","author":"SD Blackburn","year":"2007","unstructured":"Blackburn, S. D. & Wherry, E. J. IL-10, T cell exhaustion and viral persistence. Trends Microbiol. 15(4), 143\u2013146 (2007).","journal-title":"Trends Microbiol."},{"issue":"7","key":"5084_CR53","doi-asserted-by":"publisher","first-page":"3723","DOI":"10.1128\/JVI.00006-15","volume":"89","author":"KL Clayton","year":"2015","unstructured":"Clayton, K. L. et al. Soluble T cell immunoglobulin mucin domain 3 is shed from CD8+ T cells by the sheddase ADAM10, is increased in plasma during untreated HIV infection, and correlates with HIV disease progression. J. Virol. 89(7), 3723\u20133736 (2015).","journal-title":"J. Virol."},{"issue":"7","key":"5084_CR54","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1097\/QAD.0000000000002165","volume":"33","author":"E Zilber","year":"2019","unstructured":"Zilber, E. et al. Soluble plasma programmed death 1 (PD-1) and Tim-3 in primary HIV infection. AIDS 33(7), 1253\u20131256 (2019).","journal-title":"AIDS"},{"issue":"2","key":"5084_CR55","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.cellimm.2005.07.007","volume":"235","author":"C Nielsen","year":"2005","unstructured":"Nielsen, C. et al. Alternative splice variants of the human PD-1 gene. Cell. Immunol. 235(2), 109\u2013116 (2005).","journal-title":"Cell. Immunol."},{"issue":"12","key":"5084_CR56","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.it.2003.10.001","volume":"24","author":"F Triebel","year":"2003","unstructured":"Triebel, F. LAG-3: A regulator of T-cell and DC responses and its use in therapeutic vaccination. Trends Immunol. 24(12), 619\u2013622 (2003).","journal-title":"Trends Immunol."},{"issue":"4","key":"5084_CR57","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1086\/515682","volume":"178","author":"T Laskus","year":"1998","unstructured":"Laskus, T. et al. The presence of active hepatitis C virus replication in lymphoid tissue in patients coinfected with human immunodeficiency virus type 1. J. Infect. Dis. 178(4), 1189\u20131192 (1998).","journal-title":"J. Infect. Dis."},{"issue":"Pt 11","key":"5084_CR58","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1099\/0022-1317-78-11-2747","volume":"78","author":"T Laskus","year":"1997","unstructured":"Laskus, T. et al. Hepatitis C virus negative strand RNA is not detected in peripheral blood mononuclear cells and viral sequences are identical to those in serum: A case against extrahepatic replication. J. Gen. Virol. 78(Pt 11), 2747\u20132750 (1997).","journal-title":"J. Gen. Virol."},{"issue":"1","key":"5084_CR59","doi-asserted-by":"publisher","first-page":"16060","DOI":"10.1038\/s41598-020-73137-6","volume":"10","author":"S Osuch","year":"2020","unstructured":"Osuch, S. et al. Decrease of T-cells exhaustion markers programmed cell death-1 and T-cell immunoglobulin and mucin domain-containing protein 3 and plasma IL-10 levels after successful treatment of chronic hepatitis C. Sci. Rep. 10(1), 16060 (2020).","journal-title":"Sci. Rep."},{"issue":"7","key":"5084_CR60","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.1093\/molbev\/msab120","volume":"38","author":"K Tamura","year":"2021","unstructured":"Tamura, K., Stecher, G. & Kumar, S. MEGA11: Molecular evolutionary genetics analysis version 11. Mol. Biol. Evol. 38(7), 3022\u20133027 (2021).","journal-title":"Mol. Biol. Evol."},{"issue":"3","key":"5084_CR61","first-page":"237","volume":"26","author":"MM Yousif","year":"2018","unstructured":"Yousif, M. M. et al. Prevalence of occult hepatitis C virus infection in patients who achieved sustained virologic response to direct-acting antiviral agents. Infez Med 26(3), 237\u2013243 (2018).","journal-title":"Infez Med"},{"issue":"4","key":"5084_CR62","first-page":"401","volume":"72","author":"N Wada","year":"2018","unstructured":"Wada, N. et al. Mixed HCV infection of genotype 1B and other genotypes influences non-response during daclatasvir + asunaprevir combination therapy. Acta Med. Okayama 72(4), 401\u2013406 (2018).","journal-title":"Acta Med. Okayama"},{"issue":"Pt 3","key":"5084_CR63","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1099\/0022-1317-80-3-711","volume":"80","author":"SJ Jang","year":"1999","unstructured":"Jang, S. J. et al. Differences between hepatitis C virus 5\u2019 untranslated region quasispecies in serum and liver. J. Gen. Virol. 80(Pt 3), 711\u2013716 (1999).","journal-title":"J. Gen. Virol."},{"key":"5084_CR64","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/175405","volume":"2014","author":"I Bukowska-Osko","year":"2014","unstructured":"Bukowska-Osko, I. et al. Analysis of genotype 1b hepatitis C virus IRES in serum and peripheral blood mononuclear cells in patients treated with interferon and ribavirin. Biomed. Res. Int. 2014, 175405 (2014).","journal-title":"Biomed. Res. Int."},{"issue":"9","key":"5084_CR65","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005894","volume":"12","author":"J Raghwani","year":"2016","unstructured":"Raghwani, J. et al. Exceptional heterogeneity in viral evolutionary dynamics characterises chronic hepatitis C virus infection. PLoS Pathog. 12(9), e1005894 (2016).","journal-title":"PLoS Pathog."},{"issue":"7","key":"5084_CR66","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1136\/gut.2009.192088","volume":"59","author":"T Durand","year":"2010","unstructured":"Durand, T. et al. Occult infection of peripheral B cells by hepatitis C variants which have low translational efficiency in cultured hepatocytes. Gut 59(7), 934\u2013942 (2010).","journal-title":"Gut"},{"issue":"1","key":"5084_CR67","doi-asserted-by":"publisher","first-page":"iqad006","DOI":"10.1093\/oxfimm\/iqad006","volume":"4","author":"E Jenkins","year":"2023","unstructured":"Jenkins, E. et al. The current state and future of T-cell exhaustion research. Oxf. Open Immunol. 4(1), iqad006 (2023).","journal-title":"Oxf. Open Immunol."},{"issue":"6","key":"5084_CR68","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1128\/JCM.02390-07","volume":"46","author":"J Verbeeck","year":"2008","unstructured":"Verbeeck, J. et al. Evaluation of versant hepatitis C virus genotype assay (LiPA) 2.0. J. Clin. Microbiol. 46(6), 1901\u20131906 (2008).","journal-title":"J. Clin. Microbiol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-05084-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-05084-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-05084-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T11:03:01Z","timestamp":1749207781000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-05084-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,6]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5084"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-05084-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,6]]},"assertion":[{"value":"7 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19918"}}